Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males

January 2020 | Volume 19 | Issue 1 | Original Article | 78 | Copyright © January 2020


Published online December 13, 2019

Fran E. Cook-Bolden , Michael H. Gold , Eric Guenin

aMount Sinai Health System, New York, NY bTennnessee Clinical Research Center, Nashville, TN cOrtho Dermatologics, Bridgewater, NJ



19.1 and 24.2, compared with 14.4 and 21.5, respectively, in the adolescent males.

By week 12, in the adult males there was a 62.3% and 59.5% change in inflammatory and noninflammatory lesion counts from baseline (LS mean) with tazarotene 0.045% lotion, compared with 49.4% (P=0.001) and 49.5% (P=0.016) in the adolescent males (Figures 2 and 3). Efficacy differences between the adult and adolescent males were significant from week 4.

Acne-Specific QoL
At baseline, the mean scores for Self-Perception, Role-Emotional, Role-Social, and Acne Symptoms in those subjects subsequently treated with tazarotene 0.045% lotion were higher (ie, better QoL) in the adolescent males: 27.2, 27.0, 23.8, and 22.5 compared with 20.1, 21.3, 18.1, and 19.2, respectively, in the adult males. By week 12 the absolute change from baseline in Self-Perception, Role-Emotional, Role-Social and Acne Symptom domains were 3.0, 1.7, 1.8, and 3.9, respectively, in